BioCentury
ARTICLE | Clinical News

Cantab begins Phase I

June 15, 2000 7:00 AM UTC

Cantab (LSE:CTB; CNTBY) started a 40-patient Phase I trial in the Netherlands of its TA-CIN genetically engineered human papillomavirus (HPV) fusion protein vaccine to treat cervical dysplasia, an abn...